原发性系统性血管炎或风湿性多肌痛患者COVID-19结局:COVID-19全球风湿病联盟医师登记处回顾性队列研究
本研究基于COVID-19全球风湿病联盟医师登记处,纳入2020年3月12日至2021年4月12日诊断为COVID-19、且有原发性系统性血管炎或风湿性多肌痛病史的成年患者1202例,采用有序COVID-19严重程度量表,通过多因素有序logistic回归估计比值比(OR)。在1020例有结局数据的患者中,512例(50.2%)未住院、155例(15.2%)死亡;年龄较大、男性、合并症较多、泼尼松龙≥10 mg/日及疾病活动度中/高或重与更差的COVID-19结局相关。
要点
- 1020例有结局数据的患者中,155例(15.2%)死亡,239例(23.4%)住院并接受通气或补充氧气。
- 年龄每增加10岁OR 1.44(95%CI 1.31-1.57),男性较女性OR 1.38(95%CI 1.05-1.80)。
- 泼尼松龙≥10 mg/日较未用者OR 2.14(95%CI 1.50-3.04),疾病活动中/高或重较缓解/低活动OR 2.12(95%CI 1.49-3.02)。
核心结论
- 在原发性系统性血管炎和风湿性多肌痛患者中,严重COVID-19结局与年龄、性别、合并症数量等大多不可改变的危险因素以及高剂量糖皮质激素等治疗相关。
- 作者认为,其结果可用于为这些疾病患者制定缓解策略。
研究设计与样本
- 这是一项回顾性队列研究,数据来自COVID-19全球风湿病联盟医师登记处。
- 纳入2020年3月12日至2021年4月12日诊断为COVID-19、年龄≥18岁、有原发性系统性血管炎(ANCA相关性血管炎、巨细胞动脉炎、贝赫切特综合征或其他血管炎)或风湿性多肌痛病史并上报登记处的患者,共识别1202例 eligible 患者。
- 采用有序COVID-19严重程度量表:(1)未住院;(2)住院但未补充氧气;(3)住院并接受任何补充氧气或通气;(4)死亡。
- 采用多因素有序logistic回归估计OR,校正年龄、性别、时间段、合并症数量、吸烟状态、肥胖、糖皮质激素使用、疾病活动度、地区和药物类别,并按风湿病类型分层分析。
主要发现
- 1202例 eligible 患者中,733例(61.0%)为女性、469例(39.0%)为男性,平均年龄63.8岁(SD 17.1)。
- 374例(31.1%)为风湿性多肌痛,353例(29.4%)为ANCA相关性血管炎,183例(15.2%)为巨细胞动脉炎,112例(9.3%)为贝赫切特综合征,180例(15.0%)为其他血管炎。
- 1020例(84.9%)有结局数据:512例(50.2%)未住院,114例(11.2%)住院且未接受补充氧气,239例(23.4%)住院并接受通气或补充氧气,155例(15.2%)死亡。
- 年龄每增加10岁OR 1.44(95%CI 1.31-1.57);男性较女性OR 1.38(95%CI 1.05-1.80);每增加一种合并症OR 1.39(95%CI 1.23-1.58)。
- 泼尼松龙≥10 mg/日较未使用者OR 2.14(95%CI 1.50-3.04);疾病活动中/高或重较缓解或低活动OR 2.12(95%CI 1.49-3.02);不同疾病亚型间危险因素存在差异。
关键数值与推荐
- COVID-19严重程度采用4级有序量表:1级未住院;2级住院未补充氧气;3级住院并接受任何补充氧气或通气;4级死亡。
- 年龄每增加10岁与更差COVID-19结局相关,OR 1.44(95%CI 1.31-1.57)。
- 男性较女性与更差COVID-19结局相关,OR 1.38(95%CI 1.05-1.80)。
- 每增加一种合并症与更差COVID-19结局相关,OR 1.39(95%CI 1.23-1.58)。
- 泼尼松龙≥10 mg/日较未使用者OR 2.14(95%CI 1.50-3.04);疾病活动中/高或重较缓解或低活动OR 2.12(95%CI 1.49-3.02)。
临床怎么用
- 原文结论指出,年龄、性别和合并症数量等危险因素大多不可改变,而高剂量糖皮质激素等治疗相关因素也被观察到与严重COVID-19结局相关。
- 作者认为,其结果可用于为原发性系统性血管炎和风湿性多肌痛患者制定缓解策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with primary systemic vasculitis or polymyalgia rheumatica might be at a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ damage cause by primary systemic vasculitis, and the demographic factors associated with these conditions. We therefore aimed to investigate factors associated with COVID-19 outcomes in patients with primary systemic vasculitis or polymyalgia rheumatica. METHODS: In this retrospective cohort study, adult patients (aged ≥18 years) diagnosed with COVID-19 between March 12, 2020, and April 12, 2021, who had a history of primary systemic vasculitis (antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, giant cell arteritis, Behçet's syndrome, or other vasculitis) or polymyalgia rheumatica, and were reported to the COVID-19 Global Rheumatology Alliance registry were included. To assess COVID-19 outcomes in patients, we used an ordinal COVID-19 severity scale, defined as: (1) no hospitalisation; (2) hospitalisation without supplemental oxygen; (3) hospitalisation with any supplemental oxygen or ventilation; or (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs), adjusting for age, sex, time period, number of comorbidities, smoking status, obesity, glucocorticoid use, disease activity, region, and medication category. Analyses were also stratified by type of rheumatic disease. FINDINGS: Of 1202 eligible patients identified in the registry, 733 (61·0%) were women and 469 (39·0%) were men, and their mean age was 63·8 years (SD 17·1). A total of 374 (31·1%) patients had polymyalgia rheumatica, 353 (29·4%) had ANCA-associated vasculitis, 183 (15·2%) had giant cell arteritis, 112 (9·3%) had Behçet's syndrome, and 180 (15·0%) had other vasculitis. Of 1020 (84·9%) patients with outcome data, 512 (50·2%) were not hospitalised, 114 (11·2%) were hospitalised and did not receive supplemental oxygen, 239 (23·4%) were hospitalised and received ventilation or supplemental oxygen, and 155 (15·2%) died. A higher odds of poor COVID-19 outcomes were observed in patients who were older (per each additional decade of life OR 1·44 [95% CI 1·31-1·57]), were male compared with female (1·38 [1·05-1·80]), had more comorbidities (per each additional comorbidity 1·39 [1·23-1·58]), were taking 10 mg/day or more of prednisolone compared with none (2·14 [1·50-3·04]), or had moderate, or high or severe disease activity compared with those who had disease remission or low disease activity (2·12 [1·49-3·02]). Risk factors varied among different disease subtypes. INTERPRETATION: Among patients with primary systemic vasculitis and polymyalgia rheumatica, severe COVID-19 outcomes were associated with variable and largely unmodifiable risk factors, such as age, sex, and number of comorbidities, as well as treatments, including high-dose glucocorticoids. Our results could be used to inform mitigation strategies for patients with these diseases. FUNDING: American College of Rheumatology and the European Alliance of Associations for Rheumatology.
引用
- Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021. PMID: 34778843. doi:10.1016/S2665-9913(21)00316-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。